Felodipine extended-release tablets

Pharmacological action: This product is a dihydropyridine calcium channel antagonist (calcium channel blocker), which reversibly competes with nitrendipine and/or other calcium channel blockers for dihydropyridine binding sites, can block voltage-dependent Ca2 currents in vascular smooth muscle and cultured rabbit atrial cells, and blocks K-induced rat portal vein contracture. In vitro studies have shown that this product has a stronger selective inhibitory effect on vascular smooth muscle than on myocardium; negative inotropic effects can be detected in vitro, but this effect has not been observed in whole animals.

The active ingredient is felodipine.

This product is a film-coated tablet, which appears white or off-white after removing the film coating.

Hypertension (may be used alone or in combination with other antihypertensive drugs).

Oral administration, dosage should be individualized. The medication should be taken in the morning, swallowed with water, and the tablets should not be broken, crushed or chewed. 1. Treatment of hypertension: It is recommended to take 5 mg once a day as the starting treatment dose, and the commonly used maintenance dose is 5 or 10 mg once a day. The dose can be reduced or increased according to the patient's response, or other antihypertensive drugs can be added. The dose adjustment interval is generally not less than 2 weeks. 2. Treatment of angina pectoris: It is recommended to take 5 mg once a day as the starting treatment dose, and the commonly used maintenance dose is 5 or 10 mg once a day.

Common adverse reactions after taking this product are peripheral edema (mostly occurs 2 to 3 weeks after taking the drug, and the incidence is related to age and dosage), headache and facial flushing. Peripheral edema is usually mild and is related to age and dosage. Fatigue, heat sensation, palpitations, nausea, indigestion, constipation, dizziness, paresthesia, upper respiratory tract infection, cough, runny nose, sneezing, rash, and gingival hyperplasia may also be seen.

It is contraindicated for patients who are allergic to felodipine or any of the ingredients in this product, patients with decompensated heart failure, acute myocardial infarction, unstable angina pectoris, and pregnant women.

Precautions for children: There is limited experience with the use of this product in children. Precautions for pregnancy and lactation: It is contraindicated for pregnant women. Precautions for the elderly: The blood concentration of this product increases with age, so the recommended initial dose for elderly patients (over 65 years old) is 2.5 mg per day, and the dose is adjusted according to individual response.

1. The simultaneous use of certain drugs that interfere with the cytochrome P4503A4 enzyme system may affect the blood concentration of dihydropyridine calcium antagonists such as felodipine. Hepatic enzyme inhibitors (such as cimetidine, erythromycin, itraconazole, ketoconazole and certain cypermethrin compounds present in grapefruit juice) may cause an increase in the blood concentration of felodipine. Hepatic enzyme inducers (such as phenytoin, carbamazepine, rifampicin, barbiturates) may cause a decrease in the blood concentration of felodipine. 2. Felodipine does not affect the blood concentration of cyclosporine. 3. Although felodipine has a high degree of plasma protein binding, it does not affect the binding degree of other high plasma protein binding drugs (such as warfarin). 4. No significant changes in the pharmacokinetic behavior of digoxin in patients with heart failure were observed when this product was used in combination with digoxin. 5. Other drugs such as indomethacin or spironolactone have no obvious interactions with this product.

Store below 25°C.

5mg

36 months.

Laiyang Jiang Bo Pharmaceutical Co., Ltd.

• Founded in:

  2003-08-18

• Address:

  Middle section of Longmao Street, Economic Development Zone, Laiyang City, Shandong Province

• Tax NO.:

  913706827544766891

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view